Black Hawk Acquisition BKHA
Biotechnology, Healthcare
$4.70
−0.42%
- Market cap
- $19.5M
- PE
- n/m
- one or more of the four quarters through 2026-08-31 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A | $30.7K | $335.3K | $54.9K | $71.3K | $78.8K+157% | $217.6K−35% | $311.3K+467% | $187.9K+164% | $24.2K−69% | $79.2K−64% | $108.2K−65% |
| −$30.7K | −$359.2K | −$84.9K | −$101.3K | −$108.8K+254% | −$247.6K−31% | −$341.3K+302% | −$217.9K+115% | −$54.2K−50% | −$109.2K−56% | −$138.2K−60% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $19.4K | $24.4K | $33.2K |
| Net income | −$30.7K | $310.9K | $883.8K | $751.7K | $658.4K | $520.5K+67% | $154.4K−83% | −$3.8K | $139.8K−79% | $88.9K−83% | $1.1M+596% |
| n/a | n/a | n/a | n/a | $0.07 | $0.06 | $0.03 | n/a | $0.03−57% | $0.02−67% | $0.26+767% | |
| n/a | n/a | n/a | n/a | 6.9M | 6.9M | 4.1M | n/a | 2.1M−69% | 2.1M−69% | 2.1M−48% |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Black Hawk Acquisition's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BKHABlack Hawk Acquisition | $19.5M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $35.2M | 20.3× | 28.3× | 1.7× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $45M | 4.0× | 3.3× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $95.9M | 132× | 44.1× | 3.1× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| Peer median | $67M | 14.1× | 15.7× | 1.3× | +6% | 6.8% |
More on Black Hawk Acquisition
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .